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ABSTRACT   
 
A systematic review of cell models of acquired drug resistance not involving genetic 
manipulation showed that 80% of cell models had an inverse resistance relationship 
between cisplatin and paclitaxel
[1]
. Here we systematically review genetically 
modified cell lines in which the inverse cisplatin/paclitaxel resistance phenotype has 
resulted. This will form a short list of genes which may play a role in the mechanism 
of the inverse resistance relationship as well as potential markers for monitoring the 
development of resistance in the clinical treatment of cancer. The literature search 
revealed 91 genetically modified cell lines which report toxicity or viability/apoptosis 
data for cisplatin and paclitaxel relative to their parental cell lines. This resulted in 26 
genes being associated with the inverse cisplatin/paclitaxel phenotype. The gene with 
the highest number of genetically modified cell lines associated with the inverse 
resistance relationship was BRCA1 and this gene is discussed in detail with reference 
to chemotherapy response in cell lines and in the clinical treatment of breast, ovarian 
and lung cancer. Other genes associated with the inverse resistance phenotype 
included dihydrodiol dehydrogenase (DDH) and P-glycoprotein. Genes which caused 
cross resistance or cross sensitivity between cisplatin and paclitaxel were also 
examined, the majority of these genes were apoptosis associated genes which may be 
useful for predicting cross resistance. We propose that BRCA1 should be the first of a 
panel of cellular markers to predict the inverse cisplatin/paclitaxel resistance 
phenotype. 
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INTRODUCTION 
 
The chemotherapeutic drugs cisplatin and paclitaxel are used in the treatment of many 
solid tumours. Cisplatin binds to the DNA strand, hindering both DNA replication and 
RNA translation and eventually triggering apoptosis. Paclitaxel causes cytotoxicity by 
binding to and stabilising polymerised microtubules. Initial responsiveness to cisplatin 
therapy is high, however the majority of patients ultimately relapse with resistant 
disease. Mechanisms of cisplatin resistance characterised in resistant cell models 
include; decreased cellular accumulation of drug, increased levels of glutathione, 
increased levels of DNA repair and increased anti-apoptotic activity 
[2]
. Similarly, 
many patients will relapse with disease resistant to paclitaxel therapy. Paclitaxel 
resistance can be mediated by P-glycoprotein export decreasing the cellular 
accumulation 
[3]
. Other mechanisms of paclitaxel resistance include altered expression 
or post-translational modification of β-tubulin, the target of paclitaxel, or other 
microtubule regulatory proteins. Any alteration in microtubule dynamics, paclitaxel 
binding sites or signalling pathways up or downstream of microtubule polymerisation 
can potentially mediate paclitaxel resistance 
[4]
. 
 
Due to their differing mechanisms of action cisplatin and paclitaxel are often 
combined in cancer therapy. However, work in cell lines suggests that alternating 
between the two classes of drugs may be beneficial. In a recent systematic review 
article we examined the cross resistance relationship between cisplatin and paclitaxel 
in cell models of acquired drug resistance 
[1]
. The vast majority of cell models had an 
inverse resistance relationship between cisplatin and paclitaxel. When cisplatin 
resistance occurs cell lines are likely to have no change in resistance to paclitaxel and 
some cells even become hypersensitive to paclitaxel. The reverse is also true of 
paclitaxel-resistant cell lines, which either show no change in resistance to cisplatin or 
have become hypersensitive to cisplatin. This inverse resistance relationship is also 
present between other platinum drugs such as carboplatin and the newer taxane 
docetaxel. The inverse resistance relationship was present in drug-resistant cell 
models developed with both platinums or taxanes as well as those developed with 
other classes of chemotherapeutics such as anthracyclines, topoisomerase inhibitors, 
anti-metabolites and even radiation. This suggested the involvement of cellular 
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pathways that respond to a broad variety of drugs to produce either platinum 
resistance accompanied by taxane sensitivity or taxane resistance and platinum 
sensitivity. 
 
The genetic modification of cell lines by over or under expressing genes can provide 
insight into which genes are involved in resistance to a given chemotherapeutic. These 
studies will often amplify or reduce the expression of a gene to a greater extent to 
what would be observed in the development of drug resistance in cancer patients but 
nevertheless provide insight into which pathways can mediate resistance. Transfection 
studies have linked the overexpression of copper efflux transporters ATP7A 
[5]
 and 
ATP7B 
[6]
 with cisplatin resistance. Decreasing the expression of DNA repair gene 
ERCC1 by siRNA 
[7]
 or glutathione transferase GSTP1
[8]
 by antisense has been shown 
to mediate sensitivity to cisplatin. Similarly, the overexpression of ABC transporter P-
glycoprotein has been shown to mediate paclitaxel resistance 
[9]
. 
 
We undertook this systematic review to determine which genetic modifications in cell 
lines have created the inverse cisplatin/paclitaxel resistance phenotype. This will form 
a short list of genes which may play a role in the mechanism of the inverse resistance 
relationship as well as potential markers for monitoring the development of resistance 
in the clinical treatment of cancer. 
 
METHODS 
 
Medline was searched for cell lines which had been genetically modified and reported 
toxicity data for both cisplatin and paclitaxel. The following terms were used as 
keywords: ‘cisplatin’, ‘taxol’, ‘paclitaxel’, ‘cross resistance’, ‘cross resistant’, 
‘resistant’, ‘resistance’, ‘toxicity’, ‘sensitive’, ‘sensitivity’, ‘IC50’, ‘transfection’, 
‘overexpression’, ‘RNAi’, ‘antisense’, ‘siRNA’, ‘ribozyme’, ‘knockout’, 
‘knockdown’ and ‘cell line’. Review articles and articles not published in English 
were excluded. Conference presentations and abstracts were not included.  The 
literature searches were last updated in October 2008. 
 
Resistant cell models developed by selection with chemotherapy which have then 
been treated by transfection or antisense to reverse resistance were not included in the 
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systematic review process, but were used when appropriate to strengthen the case for 
identified genes being involved in the inverse resistance phenotype. Cell lines which 
had multiple genetic modifications were excluded. 
 
RESULTS AND DISCUSSION 
 
Types of Genetic Modification 
 
There are many experimental techniques to over or under express genes of interest to 
produce genetically modified cell lines for the study of genes and pathways involved 
in drug resistance. Transfection is the process of introducing nucleic acids into cells 
by non-viral methods. Most commonly plasmid DNA containing the sequence of a 
gene of interest is introduced into mammalian cells by methods such as 
electroporation or liposome-mediated transfer. This results in the gene of interest 
being overexpressed in the host cell.  This is most commonly transient overexpression 
but stable transfectants can be selected where the plasmid DNA has been integrated 
into the chromosome of the cell 
[10]
. Adenovirus vectors can also be used to 
overexpress a gene of interest 
[11]
. Transfection and adenoviruses can also be used to 
inhibit gene expression if they are used to introduce antisense oligonucleotides or 
generate small interfering RNAs (siRNA), described below.  
 
Antisense and RNA interference (RNAi) inhibition of gene expression are two 
methods which mediate post-transcriptional gene silencing based on complementary 
base pairing to the mRNA to be inhibited. Antisense uses single-stranded 
oligonucleotides of 13-15 bases which are complementary to a specific gene. The 
binding of the oligonucleotide inhibits the translation of the gene into a protein, via 
hybridizing to corresponding mRNA 
[12]
. A ribozyme is an RNA molecule that can 
catalyse a chemical reaction. A Ribozyme catalytic centre is incorporated into 
antisense RNA and specifically cleaves and destroys the target RNA. This provides an 
advantage over standard antisense technology which only inactivates the target RNA 
without degrading it 
[13]
. RNAi uses double-stranded RNAs (dsRNA) homologous to 
the gene being suppressed. Long dsRNAs are processed within the cell by dicer, a 
cellular ribonuclease III, to generate duplexes of about 21 nucleotides with 3'-
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overhangs known as small interfering RNAs (siRNAs) which mediate mRNA 
degradation 
[14]
.  
 
A gene can be knocked out from an animal in order to investigate the absence of a 
specific gene product. Gene knockout technology arose from the combination of two 
techniques: the culture of multipotent embryonic stem cells from mouse embryos and 
the induction of mutations into mammalian cells by homologous recombination. The 
embryonic stem cells could be isolated, manipulated in culture and then reintroduced 
into a wild type embryo. Knocking-in uses the same technique of homologous 
recombination as the knock-out strategy, but the targeting vector is designed to 
enhance the function of the gene of interest rather than disrupt it 
[15]
. Fibroblasts from 
knockout or knock-in mice are often studied in culture for changes in resistance to 
chemotherapy agents. 
 
Defining Resistance 
 
When genetically modified cell lines are developed in the laboratory their levels of 
resistance can be compared to their parental unmodified cells using a cell viability 
assay such as the MTT or clonogenic assay. The cisplatin and paclitaxel sensitivity of 
these paired cell lines is usually determined by exposing them to a range of drug 
concentrations and then assessing cell viability. The IC50 (drug concentration causing 
50% growth inhibition) for these paired cell lines can be used to determine the 
increase or decrease in resistance, known as fold resistance, by the following 
equation:- 
 
Fold Resistance    = IC50 of Genetically Modified Cell Line  
IC50 of Unmodified Parental Cell Line 
 
The definition of cross resistance is a matter of debate in the literature. Some studies 
consider two drugs cross-resistant only if a similar level of resistance is observed. 
Studies which have developed cell lines from patients before and after chemotherapy 
have found that drug resistance in the clinic typically produces resistance of 2 to 3- 
fold 
[16,17]
. For the purposes of this review we have defined cross resistance between 
cisplatin and paclitaxel as greater than or equal to 2-fold resistance to both drugs. This 
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definition is therefore based on what would be clinically observed as cross resistance. 
We have defined cross sensitivity as less than or equal to 0.8-fold resistance to both 
drugs. (Figure 1, indicated in black) 
 
Alternatively, many studies will not report an IC50 for their genetically modified cell 
lines. Rather, resistance or sensitivity will be defined by exposing the cell lines to a 
single dose of drug and then assaying for cell viability or level of apoptosis. We have 
reported the conclusions of the authors of these studies. Resistance was usually 
defined as a significant increase in viability or decrease in apoptosis after exposure to 
chemotherapy.  
 
The literature search revealed 91 genetically modified cell lines which report toxicity 
or viability/apoptosis data for cisplatin and paclitaxel relative to their parental cell 
lines. There are three categories of the inverse cisplatin/paclitaxel resistance 
phenotype. Non-cross resistance is where the genetic modification has induced 
resistance to one drug with no change to the other compound. Hypersensitivity is 
resistance to one drug which has induced sensitivity to the other compound (Figure 1). 
Both these categories are likely to occur in the clinical treatment of cancer, where 
resistance develops to one compound but sensitivity is present to the other. The third 
category is non-cross sensitivity, where the genetic modification has produced 
sensitivity to one agent and not altered the toxicity of the other. This category is 
unlikely to occur in the clinic but genetic modifications which produce this category 
will aid in our understanding of the inverse resistance phenotype. The areas in Figure 
1 shaded in grey are the categories of genetic modification that will aid our 
understanding of cisplatin resistance and paclitaxel sensitivity. The areas with grey 
stripes are the opposite phenotype, paclitaxel resistance and cisplatin sensitivity. 
 
Genetic Modifications Which Induce the Inverse Cisplatin/Paclitaxel Phenotype 
 
Tables 1 and 2 summarise the genetically modified cell lines which correlate with the 
inverse cisplatin/paclitaxel resistance phenotype. Table 1 covers cisplatin resistance 
and paclitaxel sensitivity and Table 2 covers paclitaxel resistance and cisplatin 
sensitivity. A total of 26 genes may therefore be associated with the inverse resistance 
phenotype. 
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Table One – Genetic Modifications Producing Cisplatin Resistance and Paclitaxel Sensitivity 
Cell Line Cancer  Modification Method Cisplatin Paclitaxel Reference  Mechanism of Resistance 
Cisplatin Resistant - Paclitaxel Sensitive 
HCC1937 Breast ↑BRCA1 Transfection Resistant Sensitive [18] 
HCC1937 Breast ↑BRCA1 Transfection 20.5 0.001 [19] 
↓Apoptosis in response to cisplatin, ↑Apoptosis in 
response to paclitaxel 
2008 Ovarian ↑DDH Transfection 7.7 0.72 
A431 Cervical ↑DDH Transfection 2.2 0.78 
Calu Lung Adenocarcinoma ↑DDH Transfection 6.3 0.59 
[20] Increase in cellular detoxification by dihydrodiol 
dehydrogenase (DDH) -cisplatin not direct substrate 
Cisplatin Resistant - Paclitaxel No Change 
A549 NSCLC ↑AKT1 Transfection 2.5 1.3 [21] Possible mechanism - Decrease in apoptosis in response to 
cisplatin 
MiaPaCa2 Pancreatic ↑ASNS Transfection Resistant No Change [22] Increased asparagine synthetase leads to ↓Apoptosis in 
response to cisplatin under glucose deprived conditions 
SKOV Ovarian ↑DDH Transfection 3 1.02 
A2780 Ovarian ↑DDH Transfection 4 0.93 
Tera Germ Cell ↑DDH Transfection 46 0.85 
[20] Increase in cellular detoxification by dihydrodiol 
dehydrogenase (DDH) -cisplatin not direct substrate 
CH1 Ovarian ↑erbB2 Transfection 2.1 1.42 [23] Mechanism not investigated 
MCF-7 Breast ↑H-Ras Transfection  9.5 1.1 
MCF-7 Breast ↑H-Ras Transfection  3.8 1 
[24]
 Decrease in DNA fragmentation induced by cisplatin 
H460 NSCLC ↑MRIT/cFLIP Transfection Resistant No Change [25] Decreased Apoptosis in response to cisplatin, by blocking 
the activation of caspase-8 
A2780 Ovarian ↑mutant p53 Transfection 2.5 1.1 [26] Mechanism not investigated 
SKBR-3 Breast ↓PKCε Antisense 2.7 1.1 [27] Decrease in DNA fragmentation induced by cisplatin 
Cisplatin No Change – Paclitaxel Sensitive 
A549 NSCLC ↓1kBa Adenovirus 1.625 0.183 [28] 1kBa Inhibits NFkB, Caspase-3 activity increased in 
response to paclitaxel Apoptosis 
MBR62 Breast ↑BRCA1 Transfection No change Sensitive [29] G2M arrest in response to paclitaxel, induction of 
GADD45 
U-20S Osteogenic Sarcoma ↑E2F-1 Transfection No change Sensitive [30] E2F-1(transcription factor) cyclin B1 levels and cdc2 
kinase activity becoming sensitive to paclitaxel 
A549 Lung ↑HERG Transfection 0.875 0.039 [31] Potassium Channel, mechanism of paclitaxel sensitivity 
unknown 
SH-EP Neuroblastoma ↑MYCN Transfection 0.94 0.51 [32] Mechanism of paclitaxel sensitivity not studied 
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Table Two – Genetic Modifications Producing Paclitaxel Resistance and Cisplatin Sensitivity 
Cell Line Cancer  Modification Method Cisplatin Paclitaxel Reference  Mechanism of Resistance 
Paclitaxel Resistant - Cisplatin Sensitive 
HBL100 Breast ↓BRCA1 Ribozyme Sensitive Resistant [33] ↓BRCA1 leads to transcriptional modifications of the JNK 
pathway ↑JNK1 ↓JNK2 
MCF-10A Mammary Epithelial ↑c-erbB2 Transfection 0.625 3.5 [34] c-erbB2 is member of the EGFR family, mechanism of 
resistance/sensitivity unknown but likely due to alteration of 
growth or apoptotic pathways  
OAW42 Ovarian ↑Survivin Transfection 0.8 6.75 [35] Increased expression of anti-apoptotic survivin ↓Apoptosis 
Paclitaxel Resistant – Cisplatin No Change  
OVCAR3 Ovarian ↑Bcl-Xl Transfection No change Resistant [36] Increased expression of anti-apoptotic Bcl-Xl ↓Apoptosis 
SKOV3 Ovarian ↓HER-2 Ribozyme 1 79 [37] Cells with decreased HER-2 accumulate in S-phase (SKOV3 
cells normally very high HER-2) 
OVCAR8 Ovarian ↑MAGE2 Transfection 1 4 
OVCAR8 Ovarian ↑MAGE6 Transfection 1 4 
[38]
 Increased Proliferation, No change in P-glycoprotein 
HeLa Ovarian ↑MRP1 Transfection 0.9 2 [39] MRP1 is a poor transporter of paclitaxel - low level 
resistance 
U-20S Osteogenic Sarcoma ↑PGK1 Transfection 1 30 [40] Increase in Phosphoglycerate Kinase 1 possibly mediating 
increased glycolysis, no change in P-gp 
MCF-7 Breast ↑P-gp Transfection 1.2 36 [9] Increased P-glycoprotein-mediated efflux of Paclitaxel 
IGROV-1 Ovarian ↑Survivin Transfection 1.25 6.6 [35] Increased expression of anti-apoptotic survivin ↓Apoptosis 
Paclitaxel No Change – Cisplatin Sensitive 
OSE Ovarian (Mouse) ↓BRCA1 Knockout 
mouse  
Sensitive No Change 
[41]
 Increase in chromosome breaks and other abberations due to 
cisplatin 
Lymphocytes Lymphocytes 
(Human) 
↓BRCA1 BRCA1 
mutation 
Sensitive No Change 
[42]
 Patients with BRCA mutation compared to healthy controls, 
mechanism not investigated 
H460 NSCLC ↑FHIT Adenovirus 0.57 1 [43] Fragile Histidine Triad (FHIT), Apoptosis 
M7609 Colon ↓GSTP1 Antisense 0.41 1.33 
M7609 Colon ↓GSTP1 Antisense 0.44 0.85 
[8]
 Decrease in detoxification of cisplatin 
HCT-116 Colon ↓p21 Knockout 0.34 0.98 
HCT-116 Colon ↓p53 E6 virus 0.23 0.98 
[44]
 Reduced DNA repair of damage due to cisplatin 
H157 Lung ↑p53wt Adenovirus 0.38 1.11 
H1299 Lung ↑p53wt Adenovirus 0.37 1.17 
[45]
 Mechanism of Cisplatin sensitivity not investigated 
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HeLa Ovarian ↑p53wt Adenovirus 0.68 0.93 [46] Increase in DNA fragmentation induced by cisplatin 
HFF Human Fibroblasts ↓RB E7 virus 0.53 0.93 [47] Mechanism of Cisplatin sensitivity not investigated 
MEF Mouse Fibroblasts ↓Xrcc2 Knockout 
mouse 
Sensitive No Change 
[48]
 Decrease in Homologous Recombination repair of DNA 
double strand breaks induced by cisplatin 
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From the literature review the gene which was correlated most highly with the inverse 
cisplatin/paclitaxel resistance phenotype was BRCA1 in six different studies 
[18,19,29,33,41,42]
. BRCA1 has been intensively investigated in many studies due to its 
role in familial breast and ovarian cancer, but has more recently been studied as a 
chemotherapy response marker in cell lines and in the clinic. When BRCA1 
expression is increased this leads to cisplatin resistance and paclitaxel sensitivity 
[18,19]
. Conversely, when BRCA1 expression is decreased this leads to paclitaxel 
resistance and cisplatin sensitivity 
[33]
. BRCA1 is the only gene identified which 
appears on both Tables 1 and 2, showing that both increases and decreases in 
expression correlate with the inverse resistance phenotype. BRCA1’s potential 
involvement with the inverse resistance mechanism will be discussed in detail later in 
this review article. 
 
Increasing the expression of anti-apoptotic survivin has been shown to cause 
paclitaxel resistance in several studies 
[49]
 and no change or sensitivity to cisplatin in 
two ovarian cancer cell lines 
[35]
. However, in studies which have only examined the 
toxicity of cisplatin and not paclitaxel, decreasing the expression of survivin caused 
cisplatin sensitivity and not resistance suggesting that survivin may not be involved in 
the inverse cisplatin/paclitaxel resistance phenotype 
[50,51]
. 
 
Increased expression of dihydrodiol dehydrogenase (DDH) has caused cisplatin 
resistance and sensitivity to paclitaxel in a panel of cell lines including ovarian, 
cervical and lung cancers 
[20]
. Increased DDH was thought to mediate cisplatin 
resistance by increasing the detoxification capability of the cell, although cisplatin is 
not a direct substrate of DDH. Increased expression of DDH has also been correlated 
with cisplatin resistance in ovarian cancer patients 
[52]
. Decreasing the expression of 
DDH has been investigated, but the toxicity of cisplatin and paclitaxel were not 
examined 
[53]
. However, the cells were rendered more sensitive to DNA binding drug 
bleomycin 
[53]
. The role of DDH in the inverse resistance phenotype requires further 
study. Examining the toxicity of cisplatin and paclitaxel in cells with decreased DDH 
expression would be an important starting point. 
 
Paclitaxel resistance can be mediated by P-glycoprotein export decreasing the cellular 
accumulation 
[3]
. Surprisingly, the literature search only revealed one cellular model 
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of increased paclitaxel resistance mediated by transfection of P-glycoprotein which 
also reported cisplatin toxicity data 
[9]
. This is most likely due to two factors: 1) 
Paclitaxel resistance mediated by P-glycoprotein is relatively easy to induce with 
paclitaxel treatment. 2) When P-glycoprotein has been transfected into cells cisplatin 
resistance may not have been examined as cisplatin is not a substrate of P-
glycoprotein. However, we know from work in resistant cell models developed with 
paclitaxel treatment that P-glycoprotein is associated with the inverse 
cisplatin/paclitaxel resistance phenotype. Resistant cell models developed using 
paclitaxel in nasal septum 
[54]
, osteosarcoma 
[55]
 and ovarian cancer cells 
[3,56]
 have 
shown levels of paclitaxel resistance ranging from 8 to 1500-fold mediated by P-
glycoprotein. There was no cross resistance to cisplatin in these cell models, many of 
which had become hypersensitive to cisplatin. 
 
There are several limitations to the identification of genes involved in the inverse 
cisplatin/paclitaxel resistance mechanism by searching the literature. Studies which 
investigate resistance to cisplatin after genetic manipulations will often only examine 
cross resistance to other platinum agents, heavy metals or other DNA targeting 
chemotherapy 
[6,7]
. Similarly, studies investigating resistance to paclitaxel may only 
examine cross resistance to other microtubule targeting agents and or P-glycoprotein 
substrates and not cisplatin 
[57]
. The other major limitation of this method is that it 
only examines genes which have already been identified, and the more popular the 
gene in terms of number of laboratories investigating it, the more likely it is to be 
examined in regards to both cisplatin and paclitaxel toxicities.  Microarray-based 
studies designed to investigate the inverse resistance phenotype will no doubt reveal 
many other genes involved in the mechanism which have not been previously 
investigated. 
 
Cisplatin/Paclitaxel Cross Resistance or Cross Sensitivity 
 
The genetic modifications which have induced cisplatin/paclitaxel cross resistance or 
cross sensitivity are itemised in Table 3. These genes are unlikely to be involved in  
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Table Three – Genetic Modifications Producing Cisplatin/Paclitaxel Cross Resistance or Cross Sensitivity 
Cell Line Cancer  Modification Method Cisplatin Paclitaxel Reference  Mechanism of Resistance 
Cross Resistance 
CHO Ovarian (Hamster) ↑ATP7A Transfection 2.4 14.6 
CHO Ovarian (Hamster) ↑ATP7A Transfection 2.5 324.95 
Me32a Fibroblast ↑ATP7A Transfection 2.4 93.39 
[5]
 Increased in cisplatin efflux mediated by copper transporter. 
Paclitaxel resistance unexplained, no efflux or presence of 
P-gp 
A2780 Ovarian ↑Aurora-A Transfection Resistant Resistant [58] Aurora-A induces survival by activating Akt growth 
signalling 
C33A Cervical ↑BAG-1  Transfection Resistant Resistant [59] Increased expression of anti-apoptotic BAG-1  ↓Apoptosis 
A2780 Ovarian ↑Bcl-Xl Transfection Resistant Resistant [60] Increased expression of anti-apoptotic Bcl-Xl  ↓Apoptosis 
HeLa Cervical ↓COX-2 siRNA Resistant Resistant [61] ↓Apoptosis in response to both cisplatin and paclitaxel 
H1299 NSCLC ↓E2F1 RNAi Resistant Resistant 
MEFS Mice Fibroblasts ↓E2F1 Knockout Resistant Resistant 
[62]
 ↓Apoptosis in response to both cisplatin and paclitaxel 
SKOV3 Ovarian ↓HtrA1 Antisense Resistant Resistant [63] Decreased expression of pro-apoptotic HtrA1  ↓Apoptosis 
EJ Bladder ↑p16 Adenovirus Resistant Resistant [64] Resistance mediated by growth arrest by replacement of 
functional p16 gene in p16 negative EJ cells 
HEC-1 Endometrial ↑PXR Transfection Resistant Resistant [65] ↓Apoptosis in response to both cisplatin and paclitaxel 
Cross Sensitivity 
A2780 Ovarian ↑Bax Adenovirus 0.18 0.48 
OVCAR-3 Ovarian ↑Bax Adenovirus 0.17 0.17 
[66]
 
MNK45 Gastric ↑Bax Transfection 0.2 0.36 [67] 
Increased expression of pro-apoptotic Bax  ↑Apoptosis 
MNK45 Gastric ↓Bcl-2 Antisense 0.34 0.28 [68] 
8305C Thyroid ↓Bcl-2 Antisense Sensitive Sensitive [69] 
HUH6 Liver ↓Bcl-2 siRNA Sensitive Sensitive [70] 
Decreased expression of anti-apoptotic Bcl-2  ↑Apoptosis 
CaOV3 Ovarian ↓Bcl-XL Antisense Sensitive Sensitive 
OVCAR3 Ovarian ↓Bcl-XL Antisense Sensitive Sensitive 
SKOV3 Ovarian ↓Bcl-XL Antisense Sensitive Sensitive 
[36]
 Decreased expression of anti-apoptotic Bcl-Xl  ↑Apoptosis 
H460 NSCLC ↓βIII Tubulin siRNA Sensitive Sensitive 
Calu-6 NSCLC ↓βIII Tubulin siRNA Sensitive Sensitive 
[71] ↑Apoptosis in response to both cisplatin and paclitaxel, 
altered microtubules and cell cycle in response to paclitaxel 
SKOV3ip1 Ovarian ↑E1A Adenovirus  Sensitive Sensitive [72] ↑Apoptosis, Increased DNA fragmentation in response to 
paclitaxel 
MEFS Mice Fibroblasts ↓E2F4 Knockout Sensitive Sensitive [62] ↑Apoptosis in response to both cisplatin and pacliaxel 
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293 Embryonic Kidney ↓E2F4 siRNA Sensitive Sensitive 
A549 NSCLC ↓EGFR Antisense 0.15 0.15 
SPC-A1 Lung 
Adenocarcinoma 
↓EGFR Antisense 0.17 0.16 
[73]
 Inhibition of growth factor Epidermal Growth Factor 
Receptor (EGFR) 
MNK45 Gastric ↑Gadd153 Transfection 0.18 0.69 [74] Possible pro-apoptotic gene 
MCF-10A Mammary Epithelial ↑Ha-Ras Transfection 0.625 0.4375 [34] Oncogene, mechanism of sensitivity not investigated 
OV167 Ovarian ↑HtrA1 Adenovirus Sensitive Sensitive [63] Serine protease HtrA1, induces cell death and activates 
caspase3/7 Apoptosis 
CNE1 Nasopharygeal ↓Id-1 siRNA Sensitive Sensitive [75] Decreased expression of anti-apoptotic Id-1  ↑Apoptosis 
DU145 Prostate ↓IGF1R Antisense Sensitive Sensitive [76] Inhibition of growth factor type 1 insulin-like growth factor 
receptor 
OV167 Ovarian ↑MCJ Transfection 0.5 0.28 [77] MCJ member of DNAJ family, more sensitive to paclitaxel 
induced apoptosis 
SH-EP Neuroblastoma ↑MYCN Transfection Sensitive Sensitive [78] ↑Apoptosis in response to both cisplatin and paclitaxel 
HFF Human Fibroblasts ↓p53 E6 virus 0.13 0.12 [47] Cell cycle alteration in response to cisplatin treatment 
PC-3 Prostate ↓PDPK Fa Antisense Sensitive Sensitive [79] Proline-directed protein kinase FA, mechanism of sensitivity 
unknown 
HEC-1 Endometrial ↓PXR siRNA Sensitive Sensitive [65] ↑Apoptosis in response to both cisplatin and paclitaxel 
KYSE-150 Esophageal ↑PUMA Adenovirus Sensitive Sensitive 
KYSE-140 Esophageal ↑PUMA Adenovirus Sensitive Sensitive 
KYSE-510 Esophageal ↑PUMA Adenovirus Sensitive Sensitive 
YES-2 Esophageal ↑PUMA Adenovirus Sensitive Sensitive 
[80]
 Increased expression of pro-apoptotic p53 upregulated 
modulator of apoptosis (PUMA)  Apoptosis 
U87-MG Glioma ↓hTR Antisense Sensitive Sensitive 
U373-MG Glioma ↓hTR Antisense Sensitive Sensitive 
[81]
 Decreased telomerase activity 
H460 NSCLC ↑TRAIL Adenovirus 0.1 0.006 [82] ↑Apoptosis in response to both cisplatin and paclitaxel - 
TRAIL (TNF-related apoptosis inducing ligand) 
T24 Bladder ↓TXAS siRNA 0.55 0.27 [83] Unknown 
TCC-SUP Bladder ↓TXAS siRNA 0.72 0.48 [83] Unknown 
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the inverse cisplatin/paclitaxel resistance phenotype but may be useful in predicting 
cross resistance between cisplatin and paclitaxel. It is interesting to note which genes 
cause generalised resistance or sensitivity to two different classes of chemotherapy. 
Some of these include well characterised apoptosis genes, decreased expression of 
anti-apoptotic Bcl-2 
[68,69]
 and Bcl-Xl 
[36]
 and increased expression of pro-apoptotic 
Bax 
[66,67]
 all cause sensitivity to both cisplatin and paclitaxel. Similarly increased 
expression of Bcl-Xl by transfection produced cross resistance to cisplatin and 
paclitaxel 
[60]
. 
 
The overexpression of ATP7A by transfection produced cross resistance between 
cisplatin and paclitaxel which was unexpected 
[5]
. Low-level resistance to cisplatin 
was mediated by ATP7As role as an efflux protein for platinum 
[84]
. The resistance to 
paclitaxel was higher and ranged from 14 to 325 – fold resistance. The mechanism of 
this resistance remains unexplained, but was not mediated by increased expression of 
P-glycoprotein or increased efflux of paclitaxel from the cell by any other transporter. 
 
Role of BRCA1 in the Inverse Cisplatin/Paclitaxel Resistance Phenotype 
 
Our systematic review of the literature found that when BRCA1 expression is 
increased cisplatin resistance and paclitaxel sensitivity occurs 
[18,19]
 and, conversely, 
when BRCA1 expression is decreased this leads to paclitaxel resistance and cisplatin 
sensitivity occurs 
[33]
. BRCA1’s role in the mechanism of cisplatin or paclitaxel 
resistance was the subject of a recent review article by Mullen et al 2006 in 
Biochimica and Biophysica Acta 
[85]
 so here we will only cover the main pathways 
influenced by BRCA1 (Figure 2), DNA repair and apoptosis, rather than a complete 
review of all the genes BRCA1 has been shown to regulate.  
 
In cisplatin-resistant MCF-7 breast cancer cells BRCA1 up-regulation is associated 
with DNA repair mediated resistance to cisplatin 
[86]
. Antisense inhibition of BRCA1 
in this same cisplatin-resistant model resulted in an increased sensitivity to cisplatin, a 
decreased proficiency of DNA repair and an enhanced rate of apoptosis. BRCA1 has 
been found to be required for the subnuclear assembly of homologous recombination 
repair protein RAD51 into foci at the site of DNA double-strand breaks due to 
cisplatin 
[87,88]
. 
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BRCA1 deficiency confers resistance to paclitaxel and has been associated with a 
defective apoptotic response in BRCA1-deficient cells, suggesting that BRCA1 could 
regulate apoptotic pathways 
[19]
 (Figure 2). BRCA1 deficiency has also been shown to 
mediate paclitaxel resistance through premature inactivation of  the spindle 
checkpoint at the metaphase anaphase transition 
[89]
 and through alterations of the 
JNK signalling pathway 
[33]
. 
 
There may be an overall inverse resistance relationship between DNA targeting 
chemotherapy and microtubule targeting chemotherapy in which BRCA1 participates. 
Increased BRCA1 expression by transfection in HCC1937 breast cancer cells leads to 
increased resistance to DNA damaging agents etoposide and bleomycin as well as 
cisplatin 
[19]
. Sensitivity to vinorelbine was also associated with increased BRCA1 
expression along with paclitaxel 
[19]
. 
 
Clinical Role for BRCA1 in Predicting Treatment Outcomes 
 
BRCA1 is an important genetic factor in hereditary breast and ovarian cancer and 
there is increasing evidence of an important role for BRCA1 in the sporadic forms of 
both cancer types 
[85]
. Therefore we sought to determine if BRCA1 mutations or 
alterations in BRCA1 mRNA and protein expression influence the response to 
cisplatin or paclitaxel-based chemotherapy. 
 
Cisplatin combination chemotherapy is the cornerstone of treatment of ovarian 
carcinomas. Initial platinum responsiveness in ovarian cancer is high, but up to 80% 
of patients will eventually relapse and become cisplatin resistant 
[90]
. Ovarian cancer 
patients with BRCA1 mutations have a higher 5-year survival rate (78.6%) compared 
to sporadic ovarian cancer (30.3%) 
[91]
. All patients in this study were treated with at 
least 2 courses of cisplatin-based chemotherapy after surgery. This correlates with the 
in vitro data, as a decrease in BRCA1 should promote sensitivity to cisplatin. 
However, when the response rate of the first-line cisplatin chemotherapy regimen is 
examined the total of complete and partial responses is the same between patients 
with a BRCA1 mutation and that of sporadic ovarian cancer. The ratio of complete to 
partial responses was slightly higher in the BRCA1 mutation cohort but due to the 
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small number of patients (7) it is unclear if this difference caused the large difference 
in survival 5 years later. Other studies have also found increased survival of BRCA1 
ovarian cancer patients over a five year period who have been treated with cisplatin- 
based therapy 
[92,93]
. However, it is difficult to determine if the choice of cisplatin- 
based chemotherapy at first line is causing the dramatic difference in outcome 5 years 
later as the salvage chemotherapy treatments given to the BRCA1 patients are often 
not recorded. Complicating this further is the fact that paclitaxel is often given as 
salvage therapy in ovarian cancer or combined with cisplatin in first-line therapy 
[1]
 
and BRCA1 mutation patients should be less responsive to paclitaxel therapy. 
 
BRCA1 mRNA and protein expression levels have also been examined in tumours 
and compared to response to chemotherapy and 5-year survival. Low BRCA1 mRNA 
levels correlated with increased response to cisplatin/gemcitabine chemotherapy and 
increased 5-year survival in a group of 55 non-small cell lung cancer patients 
[94]
. This 
again correlates with the in vitro data, as a decrease in BRCA1 should promote 
sensitivity to cisplatin. Low BRCA1 protein expression has also been shown to 
correlate with a shorter time to progression after taxane-based chemotherapy in breast 
cancer 
[95]
. This also correlates with the in vitro data, as a decrease in BRCA1 should 
promote resistance to taxanes such as paclitaxel. However, there was no decrease in 
response to taxane-based chemotherapy in these patients, just a shorter time to 
progression 
[95]
. Decreased levels of BRCA1 protein have also been shown to 
correlate with improved 5-year survival in breast cancer to other treatment regimens 
such as surgery and adjuvant radiotherapy 
[96]
 and combination treatment with 
cyclophosphamide, epirubicin and 5-fluorouracil 
[97]
. 
 
CONCLUSIONS 
 
BRCA1 is not the only gene responsible for the inverse cisplatin/paclitaxel resistance 
phenotype. BRCA1 may be over represented in the literature because of the interest in 
this gene in hereditary cancers. However, due to the large body of literature on 
BRCA1 we propose that it could be the first of a panel of cellular markers to predict 
the inverse cisplatin/paclitaxel resistance phenotype. BRCA1 mRNA or protein 
expression levels need to be further examined in tumour banks and correlated with 
both response to first and second line chemotherapy as well as time to progression and 
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5-year survival in order to fully understand the role of this protein in the inverse 
cisplatin/paclitaxel resistance phenotype. 
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Figure 1 – Defining Resistance. Resistance is defined as a fold resistance of greater than or 
equal to 2 and sensitivity as a fold resistance of less than or equal to 0.8. Cross resistance is 
therefore greater than 2-fold to both drugs and cross sensitivity less than 0.8 to both drugs, 
and are indicated in black. Non-cross resistance is resistance to one drug with no change to 
the other compound. Hypersensitivity is resistance to one drug which has induced 
sensitivity to the other compound. Non-cross sensitivity is sensitivity to one drug and no 
change to the other. Grey areas indicates the categories that will aid our understanding of 
cisplatin resistance and paclitaxel sensitivity. Areas indicated with grey stripes are the 
opposite phenotype, paclitaxel resistance and cisplatin sensitivity.
Figure 2 – Role of BRCA1 in the inverse cisplatin/paclitaxel 
resistance mechanism. On the left side of the diagram a 
decrease in BRCA1 mediates cisplatin sensitivity by 
decreasing DNA repair and increasing apoptosis in response 
to cisplatin. A decrease in BRCA1 will also mediate paclitaxel 
resistance by decreasing the apoptotic response to paclitaxel. 
On the right side of the diagram an increase in BRCA1 
mediates cisplatin resistance by increasing DNA repair and 
decreasing apoptosis in response to cisplatin. An increase in 
BRCA1 will also mediate paclitaxel sensitivity by increasing 
the apoptotic response to paclitaxel.
